News
Amgen splashes out on ChemoCentryx and its blockbuster hopef...
Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in with a $3.7 billion bid to buy out the company.
